Malawi vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Antiretroviral therapy coverage for PMTCT

Malawi
96.0%
in 2024
Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
20.1%
in 2024
Malawi rank
15th
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
14th

Antiretroviral therapy coverage for PMTCT over time

  • Malawi
  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
020406080100200020122024

How they compare

Malawi currently reports 96.0% against 20.1% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 75.9%.

That makes Malawi's figure about 4.8 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

The two have swapped places 1 time across 25 shared years of data; in 2000 it was Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ahead.

Malawi ranks 15th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 14th of 84 countries.

Malawi has averaged higher in every one of the 3 decades both report.

Head to head by decade

Decade Malawi Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Difference Ahead
2000s 15.1% 3.1% 12.0% Malawi
2010s 69.5% 17.0% 52.5% Malawi
2020s 93.6% 17.5% 76.1% Malawi

Averages of every year both report within each decade.

Frequently asked questions

Which has higher antiretroviral therapy coverage for pmtct, Malawi or Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
Malawi, at 96.0% against 20.1% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
What is the difference in antiretroviral therapy coverage for pmtct between Malawi and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
75.9%, with Malawi ahead.
How many years of comparable data are there for Malawi and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
25 years are reported by both, from 2000 to 2024.
How do Malawi and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank globally for antiretroviral therapy coverage for pmtct?
Malawi ranks 15th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 14th of 84 countries.
Where does this data come from?
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Malawi vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Antiretroviral therapy coverage for PMTCT. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 19 September 2026, from https://health.statizoid.com/compare/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/malawi/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/compare/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/malawi/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/">Malawi vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Antiretroviral therapy coverage for PMTCT</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).